知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

69 条记录 (耗时 0.048 秒)

    Method and composition for the reduction of viral replication, duration and spread of the COVID-19 and the flu
    1.
    发明授权
    Method and composition for the reduction of viral replication, duration and spread of the COVID-19 and the flu 有权

    公开(公告)号：US11628186B2

    公开(公告)日：2023-04-18

    申请号：US16974068

    申请日：2020-09-21

    申请人： Alain Martin

    发明人： Alain Martin

    IPC分类号： A61K33/42 ,  A61K9/00 ,  A61K9/08 ,  A61K33/06 ,  A61P11/00 ,  A61K31/19 ,  A61P11/06

    摘要： A method for stimulating the synthesis of nasal nitric oxide and nasal and lung surfactants to inhibit the docking and adhesion of viruses to cellular receptors, including ACE2, to reduce viral replication, duration, spread and severity of infections, and also to inhibit lung fibrosis, increase the synthesis of serotonin to reduce coughing and mouth breathing, reduce the cytokine storm produced by LI-6 caused by viruses such as COVID-19 and flu in patients susceptible to these infections, including patients with hypoxemia, asthma, chronic obstructive pulmonary disease, cystic fibrosis, diabetics, interstitial lung disease, pulmonary fibrosis, allergic rhinitis, sinusitis, smokers, sleep apnea and lung cancer, which includes: contacting mammalian cells with a therapeutically effective amount of a composition, said composition including the following constituents: sodium pyruvate; a phosphate; a salt of calcium; and a salt of magnesium.

    Methods for treatment of lung damage and for inhibition of lung fibrosis
    3.
    发明申请
    Methods for treatment of lung damage and for inhibition of lung fibrosis 审中-公开

    公开(公告)号：US20200237815A1

    公开(公告)日：2020-07-30

    申请号：US16873379

    申请日：2020-04-01

    申请人： Alain Martin

    发明人： Alain Martin

    IPC分类号： A61K33/42 ,  A61K31/19 ,  A61K33/06 ,  A61K9/08 ,  A61K9/00 ,  A61P11/00 ,  A61P11/06

    摘要： A method of stimulating the synthesis of human and animal patient lung and sinus surfactants for treatment of lung damage needed to increase lung functions, increase oxygen levels, increase the synthesis of nasal nitric oxide and for inhibition of lung fibrosis while reducing, coughing, lung tightness, mouth breathing, and reducing congestion, for treating patients with a pulmonary condition including asthma, chronic obstructive pulmonary disease, cystic fibrosis, interstitial lung disease, pulmonary fibrosis, allergic rhinitis, sinusitis, sleep apnea and lung cancer, includes: contacting mammalian cells with a therapeutically effective amount of a composition, said composition including the following constituents:sodium pyruvate; a phosphate; a salt of calcium; and, a salt of magnesium. Preferably, the composition is a saline solution.

    Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
    4.
    发明申请
    Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide 审中-公开
    通过改变土着体内一氧化氮水平来治疗哺乳动物的肺部疾病状态的方法

    公开(公告)号：US20080213403A1

    公开(公告)日：2008-09-04

    申请号：US12009647

    申请日：2008-01-22

    申请人： Alain Martin

    发明人： Alain Martin

    IPC分类号： A61K31/19 ,  A61K31/194 ,  A61K33/00 ,  A61K31/195 ,  A61K31/522 ,  A61P9/00

    CPC分类号： A61K31/19 ,  A61K31/195 ,  A61K31/198 ,  A61K31/522 ,  A61K38/28 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention provides a method for treating a pulmonary disease state in mammals by protecting indigenous in vivo levels of nitric oxide in mammalian cells comprising contacting the mammalian cells with a therapeutically effective amount of a nitric oxide mediator, wherein the nitric oxide mediator is selected from the group consisting of α-keto acids having four or more carbon atoms, precursors of α-keto acids having four or more carbon atoms, and the salts thereof.

    摘要翻译： 本发明提供了一种通过保护哺乳动物细胞中一氧化氮的本土体内水平来治疗哺乳动物的肺部疾病状态的方法，包括使哺乳动物细胞与治疗有效量的一氧化氮介体接触，其中一氧化氮介体选自 由具有四个或更多个碳原子的α-酮酸组成的组，具有四个或更多个碳原子的α-酮酸的前体及其盐。

    Therapeutic TGF-beta-wound healing compositions and methods for preparing and using same
    7.
    发明授权
    Therapeutic TGF-beta-wound healing compositions and methods for preparing and using same 失效
    治疗性TGF-β伤口愈合组合物及其制备和使用方法

    公开(公告)号：US5981606A

    公开(公告)日：1999-11-09

    申请号：US019316

    申请日：1998-02-05

    申请人： Alain Martin

    发明人： Alain Martin

    IPC分类号： A61K8/36 ,  A61K8/365 ,  A61K38/18 ,  A61Q11/00 ,  A61K31/045 ,  A61K31/07 ,  A61K31/355

    CPC分类号： A61K8/361 ,  A61K38/1841 ,  A61K8/365 ,  A61Q11/00 ,  A61K2800/522 ,  Y10S514/946 ,  Y10S514/947

    摘要： This invention pertains to therapeutic wound healing compositions for protecting and resuscitating mammalian cells (Embodiment One (I)). This invention also pertains to therapeutic TGF-beta-wound healing compositions for reducing the formation of scar tissue and increasing the proliferation and resuscitation rate of mammalian cells (Embodiment Two (II)). In a first aspect of Embodiment One (I.A), the therapeutic wound healing composition comprises (a) pyruvate, (b) an antioxidant, and (c) a mixture of saturated and unsaturated fatty acids. In a second aspect of Embodiment One (I.B), the therapeutic wound healing composition comprises (a) pyruvate, (b) lactate, and (c) a mixture of saturated and unsaturated fatty acids. In a third aspect of Embodiment One (I.C), the therapeutic wound healing composition comprises (a) an antioxidant and (b) a mixture of saturated and unsaturated fatty acids. In a fourth aspect of Embodiment One (I.D), the therapeutic wound healing composition comprises (a) lactate, (b) an antioxidant, and (c) a mixture of saturated and unsaturated fatty acids. In Embodiment Two (II), the therapeutic wound healing compositions of Embodiment One (I.A-D) are combined with a therapeutically effective amount of a TGF-beta (GF) to form TGF-beta-wound healing compositions (II.A-D+GF). This invention also pertains to methods for preparing and using the TGF-beta-wound healing compositions and the topical and ingestible pharmaceutical products in which the therapeutic compositions may be used.

    摘要翻译： 本发明涉及用于保护和复苏哺乳动物细胞的治疗性伤口愈合组合物（实施方案一（I））。 本发明还涉及用于减少瘢痕组织形成和增加哺乳动物细胞的增殖和复苏速率的治疗性TGF-β伤口愈合组合物（实施方案二（II））。 在实施方案一（I.A）的第一方面，治疗性伤口愈合组合物包含（a）丙酮酸盐，（b）抗氧化剂，和（c）饱和和不饱和脂肪酸的混合物。 在实施方案一（I.B）的第二方面，治疗性伤口愈合组合物包含（a）丙酮酸盐，（b）乳酸盐和（c）饱和和不饱和脂肪酸的混合物。 在实施方案一（I.C）的第三方面，治疗性伤口愈合组合物包含（a）抗氧化剂和（b）饱和和不饱和脂肪酸的混合物。 在实施方案一（I.D）的第四方面，治疗性伤口愈合组合物包含（a）乳酸盐，（b）抗氧化剂和（c）饱和和不饱和脂肪酸的混合物。 在实施方案二（II）中，实施方案一（IA-D）的治疗性伤口愈合组合物与治疗有效量的TGF-β（GF）组合以形成TGF-β伤口愈合组合物（II.A-D + GF）。 本发明还涉及用于制备和使用TGF-β伤口愈合组合物和其中可以使用治疗组合物的局部和可摄取药物产品的方法。